Sarepta Therapeutics, Inc. (SRPT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

17/25

Growth 3 Margin 4 Expansion 3 Platform 3 Financial 4

latest quarter score

Earnings Reports

17
SRPT Q2 2026: Cohort 8 Data Timetable Shifts, Delaying Key Regulatory Milestone to Q1
August 06, 2026
15
Sarepta (SRPT) Q4 2025: $193M Inventory Charge Resets Margin Structure as Gene Therapy Messaging Overhaul Begins
June 15, 2026
13
Sarepta Therapeutics (SRPT) Q1 2026: $325M Roche Decline Drives Cash Strength as Gene Therapy Initiatives Scale
May 07, 2026
14
SRPT Q3 2025: $300M Expense Cut Reshapes Pipeline Focus as PMO Data Faces FDA Scrutiny
November 04, 2025
12
Sarepta Therapeutics (SRPT) Q1 2025: Alevitus Revenue Jumps 180% but Guidance Cut on Cycle Delays
July 07, 2025

Browse all companies